Daily Stock Analysis, AVXL, Anavex Life Sciences Corp, priceseries

Anavex Life Sciences Corp. Daily Stock Analysis
Stock Information
Open
5.60
Close
5.70
High
5.74
Low
5.55
Previous Close
5.54
Daily Price Gain
0.16
YTD High
6.64
YTD High Date
Feb 15, 2017
YTD Low
3.95
YTD Low Date
Jan 6, 2017
YTD Price Change
1.59
YTD Gain
38.69%
52 Week High
8.30
52 Week High Date
Jul 11, 2016
52 Week Low
2.43
52 Week Low Date
Sep 21, 2016
52 Week Price Change
1.15
52 Week Gain
25.27%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jun 23. 2016
4.27
Jul 22. 2016
6.77
20 Trading Days
58.58%
Link
LONG
Nov 8. 2016
3.01
Dec 7. 2016
3.62
20 Trading Days
20.10%
Link
LONG
Jan 27. 2017
4.22
Feb 16. 2017
5.34
14 Trading Days
26.49%
Link
Company Information
Stock Symbol
AVXL
Exchange
NasdaqCM
Company URL
http://http://www.anavex.com
Company Phone
800-689-3939
CEO
Christopher U. Missling
Headquarters
New York
Business Address
51 W 52ND STREET,, 7TH FLOOR, NEW YORK, NY 10019-6163
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001314052
About

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of Alzheimer's disease, other central nervous system diseases, pain, and various cancers.

Description

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of Alzheimer's disease, other central nervous system diseases, pain, and various cancers. The company's lead drug candidates include ANAVEX 2-73 and ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil, which is in a Phase 2a clinical trial for the treatment of Alzheimer's and other central nervous system diseases. Its preclinical drug candidates include ANAVEX 3-71, which uses ligands that activate sigma-1 receptors to treat Alzheimer's disease; ANAVEX 1-41, a sigma-1 agonist that protects nerve cells from degeneration or death; and ANAVEX 1037 for the treatment of prostate cancer. The company was founded in 2006 and is based in New York, New York.